Abstract
The aim of the study was to investigate angiogenesis in patients with advanced-stage ovarian carcinoma. We used paraffin-embedded tumor tissues from 33 patients diagnosed with FIGO III ovarian cancer who had optimal surgery and received platinum-based chemotherapy. The tissue expression of CD34, vascular endothelial growth factor (VEGF), and thrombospondin-1 (TSP-1) was assessed immunohistochemically. CD34 stained hot spot areas were used to evaluate tumor microvessel density (MVD). VEGF and TSP-1 were assessed by semiquantitative methods. The studied molecules were investigated for relationship with standard clinicopathologic parameters. MVD count was high: median value of 39, range 12-143 microvessels/mm2. VEGF was present in all cases and stained strong in 91%. Stroma staining for TSP-1 was weak in 79% of the cases, strong in 6%, and absent in five (15%). We did not find correlations between the three studied markers and histologic type or tumor grade. MVD score did not relate to VEGF or TSP-1. We only observed a trend toward a longer survival in patients with tumors expressing high TSP-1 (60 vs. 36 months, P= 0.1). Proangiogenetic factor VEGF is highly expressed in advanced-stage ovarian carcinomas. The findings of this stu...Continue Reading
References
Dec 8, 1989·Science·D W LeungN Ferrara
Nov 15, 1993·Cancer·H N NguyenA Steren
Oct 10, 1997·American Journal of Obstetrics and Gynecology·O AbulafiaD M Sherer
Jan 1, 1997·British Journal of Cancer·S YamamotoT Mori
May 7, 1998·Cancer Letters·E M HartenbachS Ramakrishnan
Mar 10, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G GattaA Verdecchia
Jul 20, 2000·British Journal of Cancer·G H ShenY Sugisaki
Aug 7, 2001·British Journal of Cancer·J FujimotoT Tamaya
Sep 5, 2001·Gynecologic Oncology·A A AlvarezG C Rodriguez
Dec 26, 2001·Gynecologic Oncology·Hermann Brustmann, Susanna Naudé
May 11, 2002·Journal of Cellular and Molecular Medicine·Jack Lawler
Jun 25, 2002·Gynecologic Oncology·Michael J GoodheartRichard E Buller
Oct 3, 2002·Nature Reviews. Cancer·Napoleone Ferrara
Apr 23, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·B V OffersenJ Overgaard
May 7, 2003·Cancer·Marc T GoodmanHolly L Howe
Aug 21, 2003·Gynecologic Oncology·Philip J DiSaia, Jeffrey D Bloss
Sep 19, 2003·Gynecologic Oncology·Pamela J B StoneRichard E Buller
Dec 17, 2003·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·H T SeeR C Bast
Feb 7, 2004·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·M SönmezerF Ortaç
Apr 20, 2004·The International Journal of Biochemistry & Cell Biology·M Luisa Iruela-ArispeNathan Lee
May 29, 2004·Angiogenesis·Oddbjørn Straume, Lars A Akslen
Aug 18, 2004·Current Opinion in Oncology·Edwin M PosadasElise C Kohn
Oct 27, 2004·International Journal of Cancer. Journal International Du Cancer·Freddie BrayCarlo La Vecchia
Citations
Jun 16, 2011·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Liisa LaatioUlla Puistola
Feb 6, 2009·Nature Reviews. Cancer·Jeff S IsenbergDavid D Roberts
Sep 8, 2009·Fertility and Sterility·Xian-Jie TanLan Zhu
Dec 6, 2011·The Journal of Obstetrics and Gynaecology Research·Wei WeiXun Qu
May 7, 2015·Connective Tissue Research·Denise PinessiAndrea Resovi
Jun 14, 2014·Experimental Cell Research·Emil BujakDario Neri
Jul 21, 2012·PloS One·Shernan G HoltanMatthew P Goetz
Jan 1, 2010·Cancers·Cécile Le PageAnne-Marie Mes-Masson
Jun 12, 2013·International Journal of Molecular Sciences·Yasuyoshi Miyata, Hideki Sakai
Aug 21, 2007·Anti-cancer Drugs·Susie HongKyong-Ja Hong
Aug 16, 2013·Oncology Letters·Limei WangShuhe Wang
Jan 8, 2009·Journal of Clinical Pathology·K EngelsS Loibl
Dec 19, 2013·Oncology Letters·Jing ZhangGuangming Xu